Merck to Drop Price as Zocor Patent Lapses

The first generic versions of the popular cholesterol pill Zocor were approved by the Food and Drug Administration. The patent on Zocor, held by pharmaceutical company Merck, has run out, and that means the price for the pills will drop, as Merck has made an unusual decision to lower the price of Zocor to compete with the generics.

The decision may be bad news for Pfizer, which makes Lipitor, another popular cholesterol medication. Michele Norris talks with cardiologist Stuart Seides, associate director of cardiology at Washington Hospital Center.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

Support comes from: